HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

PeopleandPicks.com is Zacks' Community Website
Find great stocks and great stock pickers in our online community. It's social, it's profitable and it's Free! Join the fun at PeopleandPicks.com
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


THRX: Theravance Inc - Full Company Report Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Full Company Report |  Estimates |  Brokerage Recommendations |  Comparison to Industry |  Insiders |  Brokerage Reports |  Zacks Equity Research   |  Annual Report
THERAVANCE INC (NASD)
THRX 13.13 -0.27 (-2.01%) Vol.  237,305 16:00 ET
Theravance Inc is focused on the discovery, development and commercialization of small molecule medicines for unmet medical needs across a number of therapeutic areas including respiratory disease, bacterial infections, overactive bladder and gastrointestinal disorders.

 General Information
THERAVANCE INC
901 Gateway Boulevard
South San Francisco, CA 94080
Phone: 650 808-6000
Fax: 650-827-8690
Web: www.theravance.com
Email: investor.relations@theravance.com
 
Industry MED-BIOMED/GENE
Sector: Medical
 
Fiscal Year End December
Last Reported Quarter 09/30/09
Next EPS Date 02/11/2010
 
 Price and Volume Information
Zacks Rank
Yesterday's Close 13.40
52 Week High 18.56
52 Week Low 6.01
Beta 1.22
20 Day Moving Average 250,194.20
Target Price Consensus 20.29
 
 % Price Change
4 Week -9.15
12 Week -13.38
YTD 8.15
 % Price Change Relative to S&P 500
4 Week -12.62
12 Week -21.81
YTD -6.22
 Share Information
Shares Outstanding (millions) 63.56
Market Capitalization (millions) 851.73
Short Ratio 15.36
Last Split Date N/A
 Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio 0.00
Change in Payout Ratio 0.00
Last Dividend Payout / Amount NA / $0.00

 EPS Information
Current Quarter EPS Consensus Estimate -0.33
Current Year EPS Consensus Estimate -1.32
Estimated Long-Term EPS Growth Rate -
Next EPS Report Date 02/11/2010
 Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell) 2.20
30 Days Ago 2.20
60 Days Ago 2.20
90 Days Ago 2.00

 Fundamental Ratios
 P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio -
 EPS Growth
vs. Previous Year -2.94%
vs. Previous Quarter 0.00%
 Sales Growth
vs. Previous Year -8.07%
vs. Previous Quarter: 0.40%
 Price Ratios
Price/Book -
Price/Cash Flow -
Price / Sales 32.14
 ROE
09/30/09 -
06/30/09 -
03/31/09 -
 ROA
09/30/09 -36.74
06/30/09 -32.46
03/31/09 -31.07
 Current Ratio
09/30/09 4.14
06/30/09 -
03/31/09 5.08
 Quick Ratio
09/30/09 4.14
06/30/09 -
03/31/09 5.08
 Operating Margin
09/30/09 -293.23
06/30/09 -283.14
03/31/09 -284.13
 Net Margin
09/30/09 -
06/30/09 -
03/31/09 -258.16
 Pre-Tax Margin
09/30/09 -
06/30/09 -
03/31/09 -258.16
 Book Value
09/30/09 -2.80
06/30/09 -
03/31/09 -2.31
 Inventory Turnover
09/30/09 -
06/30/09 -
03/31/09 -
 Debt-to-Equity
09/30/09 -0.99
06/30/09 -
03/31/09 -1.20
 Debt to Capital
09/30/09 -
06/30/09 -
03/31/09 -

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research